STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2/47	Abstract/methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2/47-56	Abstract/methods,results
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	3/65-98	Introduction/paragrapgh 1-5
Objectives	3	State specific objectives, including any prespecified hypotheses	4/99-102	Introduction/paragraph 6
Methods				
Study design	4	Present key elements of study design early in the paper	4/105	Methods/study design
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4/106, 5/114-117	Methods/study design, Methods/data sources and measurements
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	5/110-112,114-114	Methods/participants, data sources and measurement
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5/118-139	Methods/data sources and measurement
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5/123-126	Methods/data sources and measurement
Bias	9	Describe any efforts to address potential sources of bias	5/114-117	Methods/data sources and
Study size	10	Explain how the study size was arrived at	5/110-112	Methods/participants
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6/137-140	Methods/data sources and management

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6/142-147	Methods/statistical analysis
		(b) Describe any methods used to examine subgroups and interactions	N/A	N/A
		(c) Explain how missing data were addressed	N/A	N/A
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A	N/A
		(e) Describe any sensitivity analyses	N/A	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7/155	Results/patient chracteristics
		(b) Give reasons for non-participation at each stage	N/A	N/A
		(c) Consider use of a flow diagram	N/A	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7/155-158	Results/patient chracteristics
		(b) Indicate number of participants with missing data for each variable of interest	Presented in Table 2,4	Results
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	8/215-216	Results/lanreotide use
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	7-9/159-219	Results/disease
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-9/159-219	Results/disease characteritics, treatment chracteristics, lanreotide
		(b) Report category boundaries when continuous variables were categorized	N/A	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	N/A
Discussion				
Key results	18	Summarise key results with reference to study objectives	10/221-225, 239-240	Discussion/paragraph 1,3
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12/283-285	Discussion/paragraph 9

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12/223-282	Discussion/paragraph 1-8
Generalisability	21	Discuss the generalisability (external validity) of the study results	12/283-284	Discussion/paragraph 9
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13/299	Acknowledgements/funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/jgo-22-1182
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.